Gynecologic Cancer
FDA grants regular approval to Keytruda-Lenvima combination for endometrial carcinoma
The FDA granted regular approval to the combination of pembrolizumab and lenvatinib for certain women with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.
VIDEO: Study evaluates adjuvant bevacizumab duration in ovarian cancer
In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, spoke with Healio about findings from a study examining survival with longer vs. shorter duration of bevacizumab therapy in patients with advanced ovarian cancer.
CDC reports 80% declines in breast, cervical cancer screenings during start of pandemic
Breast cancer and cervical cancer screenings declined sharply during the early part of the COVID-19 pandemic, according to CDC data released today.
HF associated with elevated risk for head and neck, lung cancers
Patients with HF had elevated risk for various cancer diagnoses vs. those without HF, especially cancers of the head and neck and respiratory organs.
VIDEO: Extended bevacizumab not beneficial in ovarian cancer
In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, discussed “hotly anticipated” results from the BOOST trial evaluating the potential benefits of extending bevacizumab therapy plus chemotherapy in newly diagnosed ovarian cancer.
VIDEO: 'Highly anticipated' trial addresses adjuvant chemotherapy in cervical cancer
In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about the OUTBACK trial presented at the ASCO Annual Meeting.
Financial toxicity, cost-coping strategies common among diverse gynecologic cancer cohort
Nearly half of a geographically diverse cohort of women with gynecologic cancer reported financial toxicity, which appeared associated with cost-coping strategies, according to a study in International Journal of Gynecological Cancer.
‘Electronic nose’ accurately detects ovarian, pancreatic cancers
An electronic, odor-based tool accurately distinguished pancreatic and ovarian cancer specimens from benign disease and control specimens by analyzing vapors emanating from blood samples, according to results of a small, preliminary study.
Mirvetuximab soravtansine plus bevacizumab ‘highly active’ in ovarian cancer subset
Mirvetuximab soravtansine in combination with bevacizumab demonstrated antitumor activity with durable responses and favorable tolerability among women with high folate receptor-alpha recurrent ovarian cancer, according to study results.
Novel vaccine safe, effective in ovarian cancer subset
A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.